drugset / Trial / NCT04434326

The Absorption, Metabolism and Excretion of [14C]CM082 in Human

NCT04434326

Phase 1 Completed 4 enrolled AnewPharma
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label, single-dose phase I study to investigate the absorption, metabolism and excretion of \[14C\] CM082 in healthy Chinese male subjects. The study will be conducted into two steps:Firstly, 2 subjects are enrolled in to participate in the pilot study to grope for the completion date of plasma, urine and feces sampling on the 3rd day post-dose and onwards. Then, the collection time of blood and excreta samples (urine and feces) from the subsequent 4-6 subjects will be adjusted according to the pilot study

Timeline

Start
2021-07-05
Primary completion
2021-10-22
Completion
2021-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject CM082 Unknown 200 mg Oral

Indications